admin – Page 8107 – Get News Story

RuggedGrade Lighting Releases New 2024 Products

Expanding on its commitment to provide premium LED lighting products, RuggedGrade Lighting has unveiled a new collection of lighting solutions for 2024 that includes a wide rollout of fixtures featuring Tunable Technology Series of Lights.

RuggedGrade Lighting, the California-based lighting manufacturer known for its innovative Tunable Technology fixtures, announced today the release of its 2024 product line. The expanded offering of high-performance LED lighting solutions empowers lighting strategies that maximize performance while saving time and money.

“Our 2024 lineup expands our best-selling Tunable Technology series to include products with smaller wattages and more shapes,” explains Miguel Parra, RuggedGrade Product Manager. “Our Tunable Technology has been on the market for two years now and has proven to be a big hit with a growing number of businesses. We are excited about this wider rollout, which integrates the technology in every instance where it would add flexibility without negatively affecting affordability.”

Tunable Technology is a RuggedGrade trademarked tech innovation that allows users to select the light color and wattage through an onboard interface. Since being introduced in 2021, it has become a customer favorite. With Tunable Technology, users don’t need to worry about color needs in advance. Fixtures can be easily changed from warm white to neutral to bright white while also adjusting wattage to provide the perfect light.

The RuggedGrade StadiumPro 4 is one of the new sports lighting fixtures in the 2024 product line, an update to the extremely popular RuggedGrade StadiumPro 3 that introduces a new 1400-watt option. It also improves the lumens per watt ratio on the 500-watt version from 135 to 150. Onboard controls on the StadiumPro 4 allow for adjustments to the wattage as well as a lumens boost.

The NextGen 4 provides an update to RuggedGrade’s best-selling parking lot series, adding Tunable Technology to the features that have made the series a top choice for organizations seeking to provide safety and convenience to their employees and customers. The Rotate 4, Orion 4, and Dorado 4 — all of which now leverage Tunable Technology to provide flexibility and adaptability — have also been added to the 2024 line.

LED lighting leverages new-age technology to provide better lighting solutions for everyday problems, delivering enhanced energy efficiency that allows organizations to better serve their lighting needs with less expense. LED lighting is also brighter, longer lasting, and safer than conventional lights — providing light with the use of mercury or UV.

“High-quality LED lighting delivers ease of use, better safety, better productivity, and a professional look that improves any commercial setting,” Parra says. “We’re excited about the ways that our 2024 product line will make LEDs even more advantageous for those who are ready to upgrade their lighting and maximize its impact and performance.”

About RuggedGrade Lighting

RuggedGrade Lighting is an innovative commercial lighting manufacturer that is owned and operated in California, USA. It is committed to providing long-term service to its customers with US-based sales and support. Its branded Tunable Technology innovation takes lighting customization to the next level, putting all of the benefits of LED lighting into a package that allows for wattage and Kelvin temperatures to be adjusted as needed through onboard controls.

Media Contact
Company Name: Otter PR
Contact Person: Pilar Lewis
Email: Send Email
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: RuggedGrade Lighting Releases New 2024 Products

Insights on Chronic Fatigue Syndrome Market 2032: Epidemiology, Pipeline Therapies, Recent Regulatory Approvals – DelveInsight | Companies- Eli Lilly, Green Cross Corp, Pfizer, Cortene, NLS Pharma

“Chronic Fatigue Syndrome Market”

DelveInsight’s “Chronic Fatigue Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Fatigue Syndrome, historical and forecasted epidemiology as well as the Chronic Fatigue Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Fatigue Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Fatigue Syndrome Market Forecast

Some of the key facts of the Chronic Fatigue Syndrome Market Report:

The Chronic Fatigue Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Between 8,36,000 and 2.5 million Americans are thought to have ME/CFS, according to a ME/CFS surveillance study done by the Centres for Disease Control and Prevention (CDC). Less than 20% of these detected instances, however, received a formal ME/CFS diagnosis, and the proportion of people with the disorder who are female can be as high as 4 to 1
According to Chu et al.’s study from 2020, “Onset Patterns and Course of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome,” the illness affects 0.76 to 3.28% of people worldwide and up to 2.5 million people in the US. CFS can strike at any age, even though the average age of start is in the 30s and women are affected at a rate that is two to three times higher than that of men
Key Chronic Fatigue Syndrome Companies: AIM ImmunoTech, Cortene, NLS Pharmaceutics, Eli Lilly and Company, Green Cross Corporation, Pfizer, AIM ImmunoTech Inc., Shire, and others
Key Chronic Fatigue Syndrome Therapies: Ampligen, CT38, NLS-4 (Lauflumide), Duloxetine, GCJBP Laennec Inj., Sildenafil (Viagra), Ampligen, Lisdexamfetamine Dimesylate, and others
The Chronic Fatigue Syndrome epidemiology based on gender analyzed that ME/CFS affects females more than the males
The Chronic Fatigue Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Fatigue Syndrome pipeline products will significantly revolutionize the Chronic Fatigue Syndrome market dynamics.

Chronic Fatigue Syndrome Overview

The multi-system condition Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), which affects the immunological, endocrine, and neurological systems, is characterised by extreme fatigue, irregular sleep patterns, pain, and other symptoms that are exacerbated by physical activity.

Get a Free sample for the Chronic Fatigue Syndrome Market Report

https://www.delveinsight.com/report-store/chronic-fatigue-syndrome-market

Chronic Fatigue Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Fatigue Syndrome Epidemiology Segmentation:

The Chronic Fatigue Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chronic Fatigue Syndrome
Prevalent Cases of Chronic Fatigue Syndrome by severity
Gender-specific Prevalence of Chronic Fatigue Syndrome
Diagnosed Cases of Episodic and Chronic Chronic Fatigue Syndrome

Download the report to understand which factors are driving Chronic Fatigue Syndrome epidemiology trends @ Chronic Fatigue Syndrome Epidemiology Forecast

Chronic Fatigue Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Fatigue Syndrome market or expected to get launched during the study period. The analysis covers Chronic Fatigue Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Fatigue Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Fatigue Syndrome Therapies and Key Companies

Ampligen: AIM ImmunoTech
CT38: Cortene
NLS-4 (Lauflumide): NLS Pharmaceutics
Duloxetine: Eli Lilly and Company
GCJBP Laennec Inj.: Green Cross Corporation
Sildenafil (Viagra): Pfizer
Ampligen: AIM ImmunoTech Inc.
Lisdexamfetamine Dimesylate: Shire

Discover more about therapies set to grab major Chronic Fatigue Syndrome market share @ Chronic Fatigue Syndrome Treatment Market

Chronic Fatigue Syndrome Market Strengths

Chronic fatigue syndrome is a frequently used modality for cancer treatment. As a result, a huge population suffers from Chronic fatigue syndrome, which presents a huge market to any new entrant.
The diagnosis of the disorder is easy with a clear clinical presentation, which helps in identifying the disease.

Chronic Fatigue Syndrome Market Unmet Needs

Challenges in diagnoses
Development of novel therapies
Limitations in gene therapy
Poor disease understanding
Clinical biomarkers

Scope of the Chronic Fatigue Syndrome Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Fatigue Syndrome Companies: AIM ImmunoTech, Cortene, NLS Pharmaceutics, Eli Lilly and Company, Green Cross Corporation, Pfizer, AIM ImmunoTech Inc., Shire, and others
Key Chronic Fatigue Syndrome Therapies: Ampligen, CT38, NLS-4 (Lauflumide), Duloxetine, GCJBP Laennec Inj., Sildenafil (Viagra), Ampligen, Lisdexamfetamine Dimesylate, and others
Chronic Fatigue Syndrome Therapeutic Assessment: Chronic Fatigue Syndrome current marketed and Chronic Fatigue Syndrome emerging therapies
Chronic Fatigue Syndrome Market Dynamics: Chronic Fatigue Syndrome market drivers and Chronic Fatigue Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chronic Fatigue Syndrome Unmet Needs, KOL’s views, Analyst’s views, Chronic Fatigue Syndrome Market Access and Reimbursement

To know more about Chronic Fatigue Syndrome companies working in the treatment market, visit @ Chronic Fatigue Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Fatigue Syndrome Market Report Introduction

2. Executive Summary for Chronic Fatigue Syndrome

3. SWOT analysis of Chronic Fatigue Syndrome

4. Chronic Fatigue Syndrome Patient Share (%) Overview at a Glance

5. Chronic Fatigue Syndrome Market Overview at a Glance

6. Chronic Fatigue Syndrome Disease Background and Overview

7. Chronic Fatigue Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Fatigue Syndrome

9. Chronic Fatigue Syndrome Current Treatment and Medical Practices

10. Chronic Fatigue Syndrome Unmet Needs

11. Chronic Fatigue Syndrome Emerging Therapies

12. Chronic Fatigue Syndrome Market Outlook

13. Country-Wise Chronic Fatigue Syndrome Market Analysis (2019–2032)

14. Chronic Fatigue Syndrome Market Access and Reimbursement of Therapies

15. Chronic Fatigue Syndrome Market Drivers

16. Chronic Fatigue Syndrome Market Barriers

17. Chronic Fatigue Syndrome Appendix

18. Chronic Fatigue Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Insights on Chronic Fatigue Syndrome Market 2032: Epidemiology, Pipeline Therapies, Recent Regulatory Approvals – DelveInsight | Companies- Eli Lilly, Green Cross Corp, Pfizer, Cortene, NLS Pharma

Insights on Next Generation Immunotherapies Market 2032: Pipeline Therapies, Latest FDA, EMA, PDMA Approvals, Epidemiology by DelveInsight | GlaxoSmithKline, Roche, Regeneron, Boehringer Ingelheim

“Next Generation Immunotherapies Market”

(Albany, USA) DelveInsight’s “Next Generation Immunotherapies Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Next Generation Immunotherapies, historical and forecasted epidemiology as well as the Next Generation Immunotherapies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Next Generation Immunotherapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Next Generation Immunotherapies Market Forecast

Some of the key facts of the Next Generation Immunotherapies Market Report:

The Next Generation Immunotherapies market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
According to the study by Atkins et al. (2022), there are over 80,000 new cases of renal cell carcinoma (RCC) and nearly 14,000 fatalities from RCC per year in the United States
The American Cancer Society predicts that in 2022, there will be roughly 287,850 new cases of invasive breast cancer in women identified in the United States
The Skin Cancer Foundation estimates that in 2022, there will be roughly 197,700 new instances of melanoma identified in the US, of which 97,920 cases will be in situ and 99,780 cases will be invasive, entering the epidermis into the dermis. Moreover, 57,180 men and 42,600 women will experience invasive cases
Prostate cancer is the most prevalent cancer in men, according to the Gustave Rossy Cancer Centre, with more than 70,000 new cases each year in France. This cancer often progresses slowly. It may be absolutely silent or the source of urinary symptoms like frequent micturition or trouble urinating
Key Next Generation Immunotherapies Companies: GlaxoSmithKline, Roche, Regeneron Pharmaceuticals, Boehringer Ingelheim, MacroGenics, MereoBiopharma, Hubao Biopharm, Shanghai Huaota Biopharmaceutical Co., Ltd., Kymab Limited, Sanofi, Alpine Immune Sciences, Inc., Xencor, Inc., Shanghai EpimAb Biotherapeutics Co., Ltd., GlaxoSmithKline, Novartis Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, AstraZeneca, Hoffmann-La Roche, Immunomic Therapeutics, Inc., Indaptus Therapeutics, Inc, Merck KGaA, Menarini Group, and others
Key Next Generation Immunotherapies Therapies: cobolimab (GSK-4069889), tiragolumab (RG-6058), Fianlimab (REGN-3767), Tebotelimab (MGD013), Ezabenlimab (BI-754091), MGC 018, Etigilimab, INCAGN02385, HB-0036, HB0036, KY1044 and atezolizumab, AZD2936, ALPN-101, Tepotinib, XmAb22841, EMB-02, TSR-022, MBG453, BMS-986213, Pemigatinib, AZD7789, RO7247669, ITI-1001, Decoy20, Avelumab, MEN1611, and others
Mesothelioma was diagnosed in 1,290 men and 340 women in Germany in 2022, according to The Robert Koch Institute (2022). A minor drop in age-standardized incidence rates is now visible more than 20 years after Germany banned the processing of asbestos, but no discernible decline in total mortality rates is yet visible
The Next Generation Immunotherapies market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Next Generation Immunotherapies pipeline products will significantly revolutionize the Next Generation Immunotherapies market dynamics.

Next Generation Immunotherapies Overview

The immune system is the main line of defence against the onset and spread of cancer. The failure of the immune system to recognise and eliminate malignant cells contributes significantly to the progression of the illness.

Get a Free sample for the Next Generation Immunotherapies Market Report

https://www.delveinsight.com/report-store/next-generation-immunotherapies-market

Next Generation Immunotherapies Epidemiology

Next Generation Immunotherapies Epidemiology Segmentation:

The Next Generation Immunotherapies market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Next Generation Immunotherapies
Prevalent Cases of Next Generation Immunotherapies by severity
Gender-specific Prevalence of Next Generation Immunotherapies
Diagnosed Cases of Episodic and Chronic Next Generation Immunotherapies

Download the report to understand which factors are driving Next Generation Immunotherapies epidemiology trends @ Next Generation Immunotherapies Epidemiology Forecast

Next Generation Immunotherapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Next Generation Immunotherapies market or expected to get launched during the study period. The analysis covers Next Generation Immunotherapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Next Generation Immunotherapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Next Generation Immunotherapies Therapies and Key Companies

Fianlimab (REGN-3767): Regeneron Pharmaceuticals
Tebotelimab (MGD013): MacroGenics
Ezabenlimab (BI-754091): Boehringer Ingelheim
cobolimab (GSK-4069889): GlaxoSmithKline
tiragolumab (RG-6058): Roche

Discover more about therapies set to grab major Next Generation Immunotherapies market share @ Next Generation Immunotherapies Treatment Market

Scope of the Next Generation Immunotherapies Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Next Generation Immunotherapies Companies: GlaxoSmithKline, Roche, Regeneron Pharmaceuticals, Boehringer Ingelheim, MacroGenics, MereoBiopharma, Hubao Biopharm, Shanghai Huaota Biopharmaceutical Co., Ltd., Kymab Limited, Sanofi, Alpine Immune Sciences, Inc., Xencor, Inc., Shanghai EpimAb Biotherapeutics Co., Ltd., GlaxoSmithKline, Novartis Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, AstraZeneca, Hoffmann-La Roche, Immunomic Therapeutics, Inc., Indaptus Therapeutics, Inc, Merck KGaA, Menarini Group, and others
Key Next Generation Immunotherapies Therapies: cobolimab (GSK-4069889), tiragolumab (RG-6058), Fianlimab (REGN-3767), Tebotelimab (MGD013), Ezabenlimab (BI-754091), MGC 018, Etigilimab, INCAGN02385, HB-0036, HB0036, KY1044 and atezolizumab, AZD2936, ALPN-101, Tepotinib, XmAb22841, EMB-02, TSR-022, MBG453, BMS-986213, Pemigatinib, AZD7789, RO7247669, ITI-1001, Decoy20, Avelumab, MEN1611, and others
Next Generation Immunotherapies Therapeutic Assessment: Next Generation Immunotherapies current marketed and Next Generation Immunotherapies emerging therapies
Next Generation Immunotherapies Market Dynamics: Next Generation Immunotherapies market drivers and Next Generation Immunotherapies market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Next Generation Immunotherapies Unmet Needs, KOL’s views, Analyst’s views, Next Generation Immunotherapies Market Access and Reimbursement

To know more about Next Generation Immunotherapies companies working in the treatment market, visit @ Next Generation Immunotherapies Clinical Trials and Therapeutic Assessment

Table of Contents

1. Next Generation Immunotherapies Market Report Introduction

2. Executive Summary for Next Generation Immunotherapies

3. SWOT analysis of Next Generation Immunotherapies

4. Next Generation Immunotherapies Patient Share (%) Overview at a Glance

5. Next Generation Immunotherapies Market Overview at a Glance

6. Next Generation Immunotherapies Disease Background and Overview

7. Next Generation Immunotherapies Epidemiology and Patient Population

8. Country-Specific Patient Population of Next Generation Immunotherapies

9. Next Generation Immunotherapies Current Treatment and Medical Practices

10. Next Generation Immunotherapies Unmet Needs

11. Next Generation Immunotherapies Emerging Therapies

12. Next Generation Immunotherapies Market Outlook

13. Country-Wise Next Generation Immunotherapies Market Analysis (2019–2032)

14. Next Generation Immunotherapies Market Access and Reimbursement of Therapies

15. Next Generation Immunotherapies Market Drivers

16. Next Generation Immunotherapies Market Barriers

17. Next Generation Immunotherapies Appendix

18. Next Generation Immunotherapies Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Insights on Next Generation Immunotherapies Market 2032: Pipeline Therapies, Latest FDA, EMA, PDMA Approvals, Epidemiology by DelveInsight | GlaxoSmithKline, Roche, Regeneron, Boehringer Ingelheim

Princeton, NJ, Realtor, Celebrates Start of 12th Year in Business

Lisa Danbrot, a real estate agent in Princeton NJ with Compass is celebrating a significant milestone in her career, beginning her 12th year as a highly respected and valued real estate professional. With a deep commitment to her clients and a wealth of experience, Lisa has become known as a trusted companion and expert guide to all who work with her.

Born and raised in Brooklyn NY, Lisa’s city-to-suburb transition that ultimately led her to Princeton New Jersey was a personal journey that now allows her to connect with clients on a unique level. She believes in the power of synergy, attracting clients who share her appreciation for the qualities that make Princeton a special place to live and call home.

“I leverage my extensive experience to assist my clients in their real estate endeavors effectively. With a background in high-pressure NYC art sales, art publishing project management, and years of practicing and teaching yoga, I bring a unique skill set to real estate. I’m committed to helping my clients navigate the market with focus and proficiency in my role as a real estate agent in Princeton NJ”.

Lisa’s passion for real estate started long ago with the search for her own first home and continued as she obsessively explored properties for herself and others. Inspired by her love of architecture, design, and the concept of home, she realized she could turn her passion into a career and obtained her license in 2012. As her path unfolded, it led to her current work as a real estate agent in Princeton NJ.

For over a decade, Lisa Danbrot has worked in some of the most competitive NJ markets. As a Princeton, NJ, Realtor, she brings all her acumen and savvy to the table. She has cultivated a reputation for her unwavering commitment to her clients, her in-depth knowledge of the local real estate market, and her strategic approach to home purchases and sales.

When asked about her distinctive real estate career, Lisa shares her enthusiasm for the future: “I’ve been in business since December 2012, so I’m celebrating an anniversary this month. I am so grateful for my work and my clients and look forward to many more years of helping people navigate the dynamic world of real estate and reach their goals in the marketplace”.

For those seeking guidance in the Princeton, NJ, real estate market, Lisa Danbrot’s experience and track record is a testament to her dedication and expertise. To learn more about Lisa and her services, visit her website at https://www.compass.com/agents/lisa-danbrot/.

Media Contact
Company Name: Lisa Danbrot Properties | Real Estate Agent in Princeton NJ
Contact Person: Lisa Danbrot
Email: Send Email
Phone: +1 917-674-4109
Address:51 Bainbridge St.
City: Princeton
State: New Jersey 08540
Country: United States
Website: https://www.compass.com/agents/lisa-danbrot/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Princeton, NJ, Realtor, Celebrates Start of 12th Year in Business

Anticipated Surge in Neurofibromatosis Market Growth, Assessed by DelveInsight | Companies – Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics

“Neurofibromatosis Market”

(Albany, USA) DelveInsight’s “Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast

Some of the key facts of the Neurofibromatosis Market Report:

The Neurofibromatosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
As per Le et al. (2022), neurofibromatosis type 1 makes up about 96% of all neurofibromatosis cases. Prevalence is 1 in 3000 births. It occurs equally between gender and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation. Neurofibromatosis type 2 makes up about 3% of all cases and has a prevalence between 1 in 33,000 births and 1 in 87,410
Around 16,874 diagnosed cases of NF-2 were found to be prevalent worldwide in 2022, with 10,508 cases found in the US alone. This number of cases is anticipated to increase between 2019 and 2032
In a research by Ejerskov et al. (2021), five patients (30%) with a mosaic form of neurofibromatosis type 1 (NF1) exhibited plexiform neurofibromas out of a total of 17 patients. In their investigation, which included nine papers as well, the researchers came to the conclusion that out of 126 individuals with MNF1, 19 (15%) of them had a plexiform neurofibroma
For paediatric patients with neurofibromatosis type 1 (NF1), a rare and disfiguring illness, aged 2 years or older, Selumetinib became the first medication to receive FDA approval in 2020.
A large number of pharmaceutical companies are entering this illness area as a result of scientific advancements. NFX-179 Gel, Mirdametinib, and FCN-159 are a few new medications
Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, NFlection Therapeutics, Inc., Merck Sharp & Dohme LLC, Shanghai Fosun Pharma, Array BioPharma, Recursion Pharma, Astrazeneca, GlaxoSmithKline, Betta Pharma, Genentech, Inc., and others
Key Neurofibromatosis Therapies: FCN-159, Mirdametinib, NFX-179 Gel, HL-085, RAD001: Everolimus, NFX-179 gel, Selumetinib, FCN-159, Trametinib, Binimetinib, REC-2282, AZD2014, Lapatinib, Icotinib, Bevacizumab, and others
The Neurofibromatosis epidemiology based on type-specific cases analyzed that the prevalent cases of Neurofibromatosis is highest for NF1
The Neurofibromatosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis pipeline products will significantly revolutionize the Neurofibromatosis market dynamics.

Neurofibromatosis Overview

A collection of hereditary diseases known as neurofibromatosis (NF) largely damage the body’s nerve cells’ ability to grow and develop. The three primary varieties of neurofibromatosis are schwannomatosis, neurofibromatosis type 1 (NF1), and type 2 (NF2). These diseases have unique clinical characteristics and are brought on by mutations in various genes.

Get a Free sample for the Neurofibromatosis Market Report – https://www.delveinsight.com/report-store/neurofibromatosis-market

Neurofibromatosis Epidemiology

Neurofibromatosis Epidemiology Segmentation:

The Neurofibromatosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Neurofibromatosis
Prevalent Cases of Neurofibromatosis by severity
Gender-specific Prevalence of Neurofibromatosis
Diagnosed Cases of Episodic and Chronic Neurofibromatosis

Download the report to understand which factors are driving Neurofibromatosis epidemiology trends @ Neurofibromatosis Epidemiology Forecast

Neurofibromatosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis market or expected to get launched during the study period. The analysis covers Neurofibromatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Neurofibromatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurofibromatosis Therapies and Key Companies

FCN-159: Fosun Pharmaceutical
Mirdametinib: SpringWorks Therapeutics
NFX-179 Gel: NFlection Therapeutics, Inc.
HL-085: Shanghai Kechow Pharma
RAD001: Everolimus: Novartis
NFX-179 gel: NFlection Therapeutics, Inc.
Selumetinib: Merck Sharp & Dohme LLC
FCN-159: Shanghai Fosun Pharma
Trametinib: Novartis
Binimetinib: Array BioPharma
REC-2282: Recursion Pharma
AZD2014: Astrazeneca
Lapatinib: GlaxoSmithKline
Icotinib: Betta Pharma
Bevacizumab: Genentech, Inc.

Discover more about therapies set to grab major Neurofibromatosis market share @ Neurofibromatosis Treatment Market

Scope of the Neurofibromatosis Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, NFlection Therapeutics, Inc., Merck Sharp & Dohme LLC, Shanghai Fosun Pharma, Array BioPharma, Recursion Pharma, Astrazeneca, GlaxoSmithKline, Betta Pharma, Genentech, Inc., and others
Key Neurofibromatosis Therapies: FCN-159, Mirdametinib, NFX-179 Gel, HL-085, RAD001: Everolimus, NFX-179 gel, Selumetinib, FCN-159, Trametinib, Binimetinib, REC-2282, AZD2014, Lapatinib, Icotinib, Bevacizumab, and others
Neurofibromatosis Therapeutic Assessment: Neurofibromatosis current marketed and Neurofibromatosis emerging therapies
Neurofibromatosis Market Dynamics: Neurofibromatosis market drivers and Neurofibromatosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Neurofibromatosis Unmet Needs, KOL’s views, Analyst’s views, Neurofibromatosis Market Access and Reimbursement

To know more about Neurofibromatosis companies working in the treatment market, visit @ Neurofibromatosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Neurofibromatosis Market Report Introduction

2. Executive Summary for Neurofibromatosis

3. SWOT analysis of Neurofibromatosis

4. Neurofibromatosis Patient Share (%) Overview at a Glance

5. Neurofibromatosis Market Overview at a Glance

6. Neurofibromatosis Disease Background and Overview

7. Neurofibromatosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Neurofibromatosis

9. Neurofibromatosis Current Treatment and Medical Practices

10. Neurofibromatosis Unmet Needs

11. Neurofibromatosis Emerging Therapies

12. Neurofibromatosis Market Outlook

13. Country-Wise Neurofibromatosis Market Analysis (2019–2032)

14. Neurofibromatosis Market Access and Reimbursement of Therapies

15. Neurofibromatosis Market Drivers

16. Neurofibromatosis Market Barriers

17. Neurofibromatosis Appendix

18. Neurofibromatosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticipated Surge in Neurofibromatosis Market Growth, Assessed by DelveInsight | Companies – Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics

Leading Real Estate Agent in Tampa, FL, Confirms: People are Buying Bigger Houses Than Before

In an exciting development for the Tampa real estate market, the leading real estate agent in the region, Aleks Pavlova, has confirmed a notable trend – people are buying bigger houses than ever before. This emerging trend showcases a growing demand for spacious, comfortable, and luxurious homes in the Tampa Bay area.

Tampa has long been a sought-after destination for homebuyers, thanks to its beautiful beaches, vibrant culture, and a thriving job market. However, recent data analyzed by Aleks Pavlova, the leading real estate agent in Tampa, FL, reveals a significant shift in the preferences of prospective homeowners. Homebuyers are increasingly prioritizing spacious living spaces, larger yards, and impressive amenities in their quest for the perfect property.

“Smith&Associates Real Estate has been at the forefront of the Tampa real estate market for years, and our extensive experience and market insight have allowed us to identify this emerging trend,” said Aleks Pavlova, who is recognized as one of the top Realtors in Tampa, FL. “Homebuyers are recognizing the value of larger homes that provide ample space for their families, remote work setups, and recreational activities.”

Key findings from Aleks Pavlova’s analysis include:

Increased Square Footage: The average size of homes purchased in Tampa has seen a substantial increase, with buyers showing a clear preference for larger living spaces.
High Demand for Outdoor Spaces: Homes with spacious yards, gardens, and outdoor amenities like pools and entertainment areas are in high demand, reflecting a growing desire for comfortable outdoor living spaces.
Customization and Luxury Features: Buyers are more inclined to invest in properties with upscale features, such as gourmet kitchens, walk-in closets, home theaters, and smart home technology.
Shift in Home Office Requirements: As remote work becomes a long-term reality for many, dedicated home office spaces or the potential for customization have become key priorities for homebuyers.

Aleks Pavlova and her team of real estate selling agents of Tampa, Florida, have been quick to adapt to this evolving market trend, connecting buyers with the perfect properties that cater to their evolving needs and preferences.

Tampa’s thriving real estate market is poised to meet these demands with a diverse selection of properties, ranging from expansive suburban homes to luxurious waterfront

estates. With low interest rates and an attractive quality of life, Tampa continues to attract homebuyers from all walks of life.

If you’re interested in learning more about the current real estate market trends in Tampa or are considering buying or selling a property in the area, don’t hesitate to contact Aleks Pavlova. With their expertise and dedication to client success, Aleks is ready to assist you in navigating this dynamic and competitive market.

For more information, visit Aleks Pavlova’s website at dreamhomestampabay.com

About the Real Estate Agent:

Aleks Pavlova is a renowned real estate professional with 7 years of experience in the Tampa, FL, market. Her commitment to excellence, in-depth market knowledge, and personalized service have earned them a reputation as a leading real estate agent in the Tampa Bay area.

Media Contact
Company Name: Aleks Pavlova | Real Estate Agent in Tampa FL
Contact Person: Aleks Pavlova
Email: Send Email
Phone: +1 239-333-9588
Address:3801 W Bay to Bay Blvd
City: Tampa
State: Florida 33629
Country: United States
Website: https://dreamhomestampabay.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Tampa, FL, Confirms: People are Buying Bigger Houses Than Before

Anticipated Expansion of Chronic Lower Back Pain Market with Strong Growth Projected during Forecast Period, by DelveInsight | Companies – Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast

“Chronic Lower Back Pain Market”

(Albany, USA) DelveInsight’s “Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Lower Back Pain Market Forecast

Some of the key facts of the Chronic Lower Back Pain Market Report:

The Chronic Lower Back Pain market size was valued approximately USD 6,227 Million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In the 7MM, there were a total of 77,300,000 prevalent cases of CLBP in 2022. It is anticipated that there would be an increase in CLBP patients in the 7MM from 2019 to 2032
Spain had the highest prevalence of CLBP cases in the EU4 with 8,930,000 cases, followed by the UK with 6,040,000 cases in 2022
In 2022, there were 12,700,000 cases of Chronic Lower Back Pain in Japan.
In February 2023, Camurus withdrew the CAM2038 application once it was expanded to cover chronic pain.
In February 2023, Rexlemestrocel-L was given the RMAT designation by the FDA for regenerative medicine advanced therapy (chronic lower back pain).
Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
The Chronic Lower Back Pain epidemiology based on gender analyzed that most of the CLBP cases include female population as compared to male patient pool
The Chronic Lower Back Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Lower Back Pain pipeline products will significantly revolutionize the Chronic Lower Back Pain market dynamics.

Chronic Lower Back Pain Overview

Acute low back pain can be caused by an injury or other underlying condition, but chronic low back pain (CLBP) lasts for 12 weeks or more. Everyone has had low back pain at some point because it is so prevalent.

Get a Free sample for the Chronic Lower Back Pain Market Report – https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market

Chronic Lower Back Pain Epidemiology

Chronic Lower Back Pain Epidemiology Segmentation:

The Chronic Lower Back Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chronic Lower Back Pain
Prevalent Cases of Chronic Lower Back Pain by severity
Gender-specific Prevalence of Chronic Lower Back Pain
Diagnosed Cases of Episodic and Chronic Chronic Lower Back Pain

Download the report to understand which factors are driving Chronic Lower Back Pain epidemiology trends @ Chronic Lower Back Pain Epidemiology Forecast

Chronic Lower Back Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to get launched during the study period. The analysis covers Chronic Lower Back Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Chronic Lower Back Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Lower Back Pain Therapies and Key Companies

LY3016859: Eli Lilly and Company
Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
Semdexa (SP-102): Scilex Holding
Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
AMG0103: AnGes MG, Inc
Duloxetine: Eli Lilly and Company
buprenorphine: Braeburn Pharmaceuticals
Celebrex 200mg: Pfizer
Oxymorphone ER: Endo Pharmaceuticals
PP353: Persica Pharmaceuticals
Oxycodone DETERx: Collegium Pharma
Bicifadine: DOV Pharma
OROS hydromorphone: Mallinckrodt
EN3324 (axomadol): Grünenthal GmbH
ABT-712: AbbVie

Discover more about therapies set to grab major Chronic Lower Back Pain market share @ Chronic Lower Back Pain Treatment Market

Scope of the Chronic Lower Back Pain Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
Chronic Lower Back Pain Therapeutic Assessment: Chronic Lower Back Pain current marketed and Chronic Lower Back Pain emerging therapies
Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain market drivers and Chronic Lower Back Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chronic Lower Back Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Lower Back Pain Market Access and Reimbursement

To know more about Chronic Lower Back Pain companies working in the treatment market, visit @ Chronic Lower Back Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Lower Back Pain Market Report Introduction

2. Executive Summary for Chronic Lower Back Pain

3. SWOT analysis of Chronic Lower Back Pain

4. Chronic Lower Back Pain Patient Share (%) Overview at a Glance

5. Chronic Lower Back Pain Market Overview at a Glance

6. Chronic Lower Back Pain Disease Background and Overview

7. Chronic Lower Back Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Lower Back Pain

9. Chronic Lower Back Pain Current Treatment and Medical Practices

10. Chronic Lower Back Pain Unmet Needs

11. Chronic Lower Back Pain Emerging Therapies

12. Chronic Lower Back Pain Market Outlook

13. Country-Wise Chronic Lower Back Pain Market Analysis (2019–2032)

14. Chronic Lower Back Pain Market Access and Reimbursement of Therapies

15. Chronic Lower Back Pain Market Drivers

16. Chronic Lower Back Pain Market Barriers

17. Chronic Lower Back Pain Appendix

18. Chronic Lower Back Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticipated Expansion of Chronic Lower Back Pain Market with Strong Growth Projected during Forecast Period, by DelveInsight | Companies – Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast

Top Real Estate Agent in Queens, NY, Celebrates 25 Years in Business

Ahmed Drake, the owner/broker of Innovative Solutions Realty, is celebrating a remarkable milestone in his real estate career as he marks 25 years of dedicated service. With an unwavering commitment to ethical and transparent practices, Ahmed Drake has earned his place as a respected figure in the real estate industry.

Drake’s approach to real estate is a testament to his extensive experience and dedication to his clients as a real estate agent in Queens NY. Unlike many competitors, he provides a comprehensive service that goes beyond the transaction. His holistic approach includes educating clients about the intricacies of the real estate market, guiding them through every step, and ensuring that they make informed, life-enhancing decisions.

“As the owner/broker of Innovative Solutions Realty, I bring over 20 years of combined experience as a Real Estate Agent and Broker licensed in multiple states,” says Ahmed Drake. “My passion lies in not only navigating the real estate market but also in educating and empowering clients, enhancing their understanding of the real estate market and its nuances in the realm of property investment and ownership.”

Innovative Solutions Realty, founded by Ahmed Drake in 2021, is a testament to his dedication and expertise in the real estate industry. With over two decades of experience, Ahmed Drake has consistently provided unparalleled service, marrying the wisdom of years with time-honored expertise and modern, innovative approaches.

“At Innovative Solutions Realty, our mission is to serve our clients with integrity and transparency,” says Ahmed Drake, one of the leading Realtor agents in Queens NY. “We believe in the power of knowledge and strive to ensure that our clients not only achieve their real estate goals but also gain a deeper understanding of the real estate market and the financial implications of their decisions.”

As a respected Queens, NY, Realtor, Ahmed Drake continues to set the standard for excellence in the industry. His dedication to empowering clients through education and his commitment to ethical practices have earned him the trust and respect of buyers and sellers alike.

Ahmed Drake is the owner/broker of Innovative Solutions Realty, a leading real estate agency in Queens, NY. With over 20 years of experience as a real estate agent/broker, Ahmed Drake is committed to providing comprehensive and transparent service to his clients.

Media Contact
Company Name: INNOVATIVE SOLUTIONS REALTY | Real Estate Agent in Queens, NY
Contact Person: Admed Drake
Email: Send Email
Phone: +1 929-335-7700
Address:176-27 137th Ave
City: Queens
State: New York 11434
Country: United States
Website: https://www.innovativesolutionsrealty.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Queens, NY, Celebrates 25 Years in Business

Leading Real Estate Agent in Beaufort, SC, Celebrates 8th Year In Business

Chuck Newton was looking for a new home and a chance to start another successful business. After selling real estate in ten states and two countries, Newton had the ability and understanding of the real estate industry to find success.

This was eight years ago as a buyer’s agent. Today, Newton is a successful real estate agent in Beaufort, South Carolina. Recognized by many as the leading Realtor in the area for many years, Newton notes his success did not come easily. It has taken hard work and dedication to the craft.

“My history of real estate success is part of the reason why so many people choose me as their real estate listing agent Beaufort, SC. I have followed the market and its changes carefully. This means I help the buyers and sellers find the best of the best. In the end, both are happy,” said Newton.

Outside of his knowledge, Newton works hard for his clients and customers, providing unmatched attention and customer service. This means being honest and forthright, helping clients make the concessions they often have to make when it comes to a home.

“I do everything I can for my clients and do it with a professional approach and professional experience that is unmatched with many real estate agents Beaufort, SC,” continued Newton.

Chuck Newton and the Bay Street Realty Group of Beaufort South Carolina have a highly dynamic and active website with properties coming onto and off of the market regularly. Go to https://cnewton.baystreetrealtygroup.com/ for details.

Media Contact
Company Name: Chuck Newton – Bay Street Realty Group | Real Estate Agent in Beaufort SC
Contact Person: Chuck Newton
Email: Send Email
Phone: +1 843-838-1888
Address:701 Bay Street
City: Beaufort
State: South Carolina 29902
Country: United States
Website: https://cnewton.baystreetrealtygroup.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Beaufort, SC, Celebrates 8th Year In Business

Leading Real Estate Agent in Tulsa, OK, Celebrates 22 Years in Business

Tulsa, Oklahoma is a major metropolitan city with a booming industry sector. This means plenty of people are coming into the city and its many neighborhoods with regularity. They all have one thing in common – they are all looking for a new home.

This means new residents will need the services of a real estate agent in Tulsa, OK. The better choices have a history of success and longevity in the business. There is one agent who is in their third decade of business and is still going strong – the agent that has been recognized as the top Realtor in the area for many years.

Tammy Perry is known as one of the best real estate agents Tulsa, Oklahoma, has to offer. After 22 years, she has helped countless families and individuals find their first or final home. She attributes her success in the industry to the care she has before, during and after each sale as well as one more important element.

“I would guess 80 percent of my business comes from previous clients making recommendations and looking for another home, and that alone says a lot” said Perry.

Perry also has a unique understanding of the Tulsa metro market. This means finding the perfect home for any buyer is something many other Realtors in the area might struggle with.

Tammy Perry is a Realtor agent in Tulsa, Oklahoma, with McGraw Realtors. Their website has a number of available properties entering and leaving the market with regularity. Visit https://www.mcgrawrealtors.com/Bio/tperry for contact information and properties.

Media Contact
Company Name: Tammy Perry – McGraw Realtors | Real Estate Agent in Tulsa OK
Contact Person: Tammy Perry
Email: Send Email
Phone: +1 918-906-8064
Address:10712 S Memorial Dr.
City: Tulsa
State: Oklahoma 74133
Country: United States
Website: https://www.mcgrawrealtors.com/bio/tperry

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Tulsa, OK, Celebrates 22 Years in Business